Fourth Quarter Revenue Grows 32% Year-Over-Year to $195.3 millionFourth Quarter GAAP Net Income Increases to $57.8 million and Adjusted EBITDA Grows 32% Year-Over-YearFull Year Revenue Grows 38% Year-Over-Year to $692.5 millionFull Year GAAP Net Income Increases to $99.3 million and Adjusted EBITDA Grows 62% Year-Over-YearGenerates Full Year 2025 Operating Cash Flow of $95.4 million CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, to ...

Record full year revenue of $888.3 millionFull year net income of $73.5 million (Adjusted net income of $81.6 million)Record full year Adjusted EBITDA of $171.3 million HOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the fourth quarter and year ended December 31, 2025 and the signing of two international offshore energy contrac ...

MENLO PARK, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced that it will be participating in the upcoming Citizens Technology Conference on Monday, March 2, 2026. Robinhood’s Chief Financial Officer Shiv Verma is scheduled to present on Monday, March 2, 2026, at 2:00 PM ET / 11:00 AM PT. Interested parties may access a live audio webcast of the presentation by visiting investors.robinhood.com. Following the presentation, a recording will be avai ...

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-Nationa ...

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWS ...

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. East ...

Core Insights - ORIC Pharmaceuticals reported promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][3] Financial Highlights - The company raised $264 million from healthcare specialist funds, providing a cash runway into the second half of 2028 [1] - As of December 31, 2025, cash, cash equivalents, and investments totaled $392.3 million, with an additional $20 million raised post-quarter, resulting in pro forma cash and investments of $412.3 million [5][6] Clinical Development Updates - Rinzimetostat demonstrated significant PSA responses and ctDNA reductions in mCRPC patients, with 55% achieving a PSA50 response and 20% achieving a PSA90 response [4] - Enozertinib showed competitive systemic and intracranial activity in NSCLC patients, with a 67% overall response rate (ORR) in EGFR exon 20 mutations and 80% ORR in EGFR PACC mutations [7] - The company plans to initiate a global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026 and expects multiple clinical data readouts in 2026 [5][6] Research and Development Expenses - R&D expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, and for the full year, R&D expenses were $109.8 million compared to $114.1 million in 2024 [6][13] - General and administrative expenses increased to $8.7 million for Q4 2025 from $7.6 million in Q4 2024, reflecting higher personnel costs and professional services [6][13] Upcoming Milestones - Anticipated milestones include combination dose optimization data for rinzimetostat in Q1 2026 and monotherapy data for enozertinib in the second half of 2026 [5][6]

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wedne ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 10: ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Blue Gold Limited (Nasdaq: BGL) (“Blue Gold” or the “Company”), a next-generation gold development and technology company, today announced that it has withdrawn its suits pending before the Courts of Ghana, and does not currently intend to pursue any other legal avenues open to it in Ghana. The Company has taken this step to concentrate its legal efforts and resources exclusively on the ongoing international arbitration proceedings, which it is pursuing under the ...